Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

Key Takeaways GILD leads HIV space with Biktarvy, Descovy and new PrEP drug Yeztugo driving momentum. GILD sees stronger 2025 HIV revenue growth and posts gains across liver disease and oncology.GILD outperforms on price performance while BMY faces legacy drug pressure and higher debt.Bristol Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD) are leading biotechnology companies with broad, diverse portfolios and a global footprint.BMY boasts a strong portfolio with drugs for oncology, hematology, immunolog ...